The impact of “faster aspart” on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump

Nathan, 1993, The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 Diabetes Control and Complications Trial Research Group, 1994, The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial, J Pediatr, 125, 177, 10.1016/S0022-3476(94)70190-3 Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, 1999, Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort, Diabetes Care, 22, 99, 10.2337/diacare.22.1.99 DiMeglio, 2018, ISPAD Clinical Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents and young adults with diabetes, Pediatr Diabetes, 19, 105, 10.1111/pedi.12737 Foster, 2019, State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018, Diabetes Technol Ther, 21, 66, 10.1089/dia.2018.0384 Danne, 2018, ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes, Pediatr Diabetes, 19, 115, 10.1111/pedi.12718 Sherr, 2016, Use of insulin pumptherapy in children and adolescents wityh type 1 diabetes and its impact on metabolic control: comparison of results from three large transatlantic paediatric registries, Diabetología., 59, 87, 10.1007/s00125-015-3790-6 Fatourechi, 2009, Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continous subcutaneous insulin infusion versus multiple daily injections, J Clin Endocrinol Metab, 94, 729, 10.1210/jc.2008-1415 Ampudia-Blasco, 2010, Hiperglucemia posprandrial y variabilidad glucémica: nuevos objetivos de control de la diabetes, Av Diabetol, 26, 29 American Diabetes Association, 2020, Children and Adolescents: Standards of Medical Care in Diabetes-2020, Diabetes Care, 43, S163, 10.2337/dc20-S013 Monnier, 2003, Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c), Diabetes Care, 26, 881, 10.2337/diacare.26.3.881 Standl, 2011, Postprandial hyperglycemia and glycemic variability: should we care?, Diabetes Care, 34, 120, 10.2337/dc11-s206 Bergman, 2016, One-hour post-load plasma glucose level during the OGTT predicts mortality: observations from the Israel study of glucose intolerance, obesity and hypertension, Diabet Med, 33, 1060, 10.1111/dme.13116 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 The NAVIGATOR Study Group, 2010, Effect of nateglinide on the incidence of diabetes and cardiovascular events, N England J Med, 362, 1463, 10.1056/NEJMoa1001122 Biester, 2018, Pharmacotherapy of type 1 diabetes in children and adolescents: more than insulin?, Ther Adv Endocrinol Metab, 9, 157, 10.1177/2042018818763247 Heinemann, 2012, Ultrafast-acting insulins: state of the art, J Diabetes Sci Technol, 6, 728, 10.1177/193229681200600402 Gingras, 2018, The challenges of achieving postprandial glucose control using closed-loops systems in patients with type 1 diabetes, Diabetes Obes Metab, 20, 245, 10.1111/dom.13052 Kildegaard, 2019, Elucidating the mechanism of absorption of fast-acting insulin aspart: the role of niacinamide, Pharm Res, 36, 49, 10.1007/s11095-019-2578-7 Heise, 2017, A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes, Clin Pharmacokinet, 56, 551, 10.1007/s40262-017-0514-8 Fath, 2017, Faster-acting insulin aspart provides faster onset and greater early exposure vc insulin aspart in chidren and adolescent with type 1 diabetes mellitus, Pediatr Diabetes, 18, 903, 10.1111/pedi.12506 Heise, 2017, Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continous subcutaneous insulin infusion: a randomized, double-blind, crossover trial, Diabetes Obes Metab, 19, 208, 10.1111/dom.12803 Bode, 2019, Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial, Diabetes Care, 42, 1255, 10.2337/dc19-0009 Battelino, 2019, Clinical targets for continous glucose monitoring data interpretation: recommendations from the international consensus on time in range, Diabetes Care, 42, 1593, 10.2337/dci19-0028 Carrascosa, 2008, Estudio transversal español de crecimiento 2008. Parte II: valores de talla, peso e índice de masa corporal desde el nacimiento a la talla adulta, An Pediatr, 68, 552, 10.1157/13123287 Russell-Jones, 2017, Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1), Diabetes Care, 40, 943, 10.2337/dc16-1771 Klonoff, 2019, A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5), Diabetes Obes Metab, 21, 961, 10.1111/dom.13610 Bode, 2017, Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using continous subcutaneous insulin infusion, Diabetes Technol Ther, 19, 25, 10.1089/dia.2016.0350 Beck, 2019, The relationships between time in range, hyperglycemia metrics and hbA1c, Diabetes Sci Technol, 13, 614, 10.1177/1932296818822496 Vigersky, 2019, The relationship of hemoglobin A1C to time-in-range in patients with diabetes, Diabetes Technol Ther, 21, 81, 10.1089/dia.2018.0310 Evans, 2019, Use of fast-acting insulin aspart in insulin pump therapy in clinical practice, Diabetes Obes Metab, 1 European Medicines Agency, 2017 Regittnig, 2019, Insulin bolus administration in insulin pump therapy: effect of bolus delivery speed on insulin absorption from subcutaneous tissue, Diabetes Technol Ther, 21, 44, 10.1089/dia.2018.0295 Buse, 2018, Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial, Diabetes Obes Metab, 20, 2885, 10.1111/dom.13545 Pettus, 2017, Recommendtions for using real-time continous glucose monitoring (rtCGM) for insulin adjustments in type 1 diabetes, J Diabetes Sci Technol, 11, 138, 10.1177/1932296816663747 Laffel, 2017, A practical approach using trend arrows on the Dexcom G5 CGM system to manage children and adolescents with diabetes, J Endocr Soc, 1, 1461, 10.1210/js.2017-00389 Zijlstra, 2018, Investigation of pump compatibility of fast-acting insulin aspart in continuous subcutaneous insulin infusion in subjects with type 1 diabetes, J Diabetes Sci Technol, 12, 145, 10.1177/1932296817730375 Overmann, 1999, Injection-meal interval: recommendations of diabetologists and how patients handle it, Diabetes Res Clin Pract, 43, 137, 10.1016/S0168-8227(98)00132-6 Ahern, 2002, Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups, Pediatr Diabetes, 3, 10, 10.1034/j.1399-5448.2002.30103.x